Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: Full, partial and inverse agonism

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 1, 2010, Pages 1-5

  Hanania, Nicola A ^a   Dickey, Burton F ^b   Bond, Richard A ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

Author keywords

2 adrenoceptor agonist; Asthma; B adrenoceptor inverse agonist; B blocker; Chronic

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FORMOTEROL; ISOPRENALINE; NADOLOL; SALBUTAMOL; SALMETEROL;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHITIS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COMORBIDITY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; GENOTYPE; HEART ARRHYTHMIA; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; INTENSIVE CARE UNIT; INTUBATION; INVERSE AGONISM; LIPOPHILICITY; LUNG FUNCTION; METAPLASIA; MORTALITY; NONHUMAN; PARTIAL AGONISM; RECEPTOR AFFINITY; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RESPIRATORY EPITHELIUM; REVIEW; SINGLE DRUG DOSE; TACHYCARDIA; TREATMENT DURATION; TREMOR;

ADRENERGIC BETA-AGONISTS; ASTHMA; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RESPIRATORY HYPERSENSITIVITY; TREATMENT OUTCOME;

EID: 74549190628     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328333def8     Document Type: Review

References (52)

1. Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma: summary report 2007. J Allergy Clin Immunol 2007; 120:S94-S138.
2. Hanania NA, Sharafkhaneh A, Barber R, Dickey BF. Beta-agonist intrinsic efficacy: measurement and clinical significance. Am J Respir Crit Care Med 2002; 165:1353-1358.
3. Hanania NA, Moore RH. Anti-inflammatory activities of beta2-agonists. Curr Drug Targets Inflamm Allergy 2004; 3:271-277.
4. Sindi A, Todd DC, Nair P. Antiinflammatory effects of long-acting beta2- agonists in patients with asthma: a systematic review and meta-analysis. Chest 2009; 136:145-154.
5. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009; 34:757-769.
6. Mansfield LE. The future of the long-acting beta-adrenergic bronchodilators in the treatment of asthma. Allergy Asthma Proc 2008; 29:103-108.
7. Parra S, Bond RA. Inverse agonism: from curiosity to accepted dogma, but is it clinically relevant? Curr Opin Pharmacol 2007; 7:146-150.
8. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004; 125:1081-1102.
9. Hanania NA, Moore RH, Zimmerman JL, et al. The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med 2007; 101:1007-1014.
10. Bremner P, Siebers R, Crane J, et al. Partial vs. full beta-receptor agonism. A clinical study of inhaled albuterol and fenoterol. Chest 1996; 109:957-962.
11. Lipworth BJ, Newnham DM, Clark RA, et al. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50:54-61.
12. Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160:244-249.
13. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6:204-210.
14. Bremner P, Burgess C, Beasley R, et al. Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmatics. Respir Med 1992; 86:419-423.
15. Pearce N. The use of beta agonists and the risk of death and near death from asthma. J Clin Epidemiol 2009; 62:582-587.
16. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364:1505-1512.
17. Israel E, Drazen JM, Liggett SB, et al. Effect of polymorphism of the beta(2)- adrenergic receptor on response to regular use of albuterol in asthma. Int Arch Allergy Immunol 2001; 124:183-186.
18. Drazen JM, O'Byrne PM. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009; 360:1671-1672.
19. Kramer JM. Balancing the benefits and risks of inhaled long-acting betaagonists- the influence of values. N Engl J Med 2009; 360:1592-1595.
20. Taylor DR. The beta-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med 2009; 179:976-978.
21. Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest 2009; 136:604-607.
22. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
23. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 2003; 124:70-74.
24. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 2009; 33:21-32.
25. Wijesinghe M, Perrin K, Harwood M, et al. The risk of asthma mortality with inhaled long acting beta-agonists. Postgrad Med J 2008; 84:467-472.
26. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009;CD006922.
27. Cates CJ, Lasserson TJ, Jaeschke R. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2009;CD006924.
28. Jaeschke R, O'Byrne PM, Nair P, et al. The safety of formoterol among patients with asthma using inhaled corticosteroids. Systematic review and metaanalysis. Pol Arch Med Wewn 2008; 118:627-635.
29. Rodrigo GJ,Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma. A systematic review. Pulm Pharmacol Ther 2009; 22:9-19.
30. Nielson CP, Hadjokas NE. Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med 1998; 157:184-191.
31. Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A 2004; 101:4948-4953.
32. Lommatzsch M, Lindner Y, Edner A, et al. Adverse effects of salmeterol in asthma: a neuronal perspective. Thorax 2009; 64:763-769.
33. Lipworth BJ. Antagonism of long-acting beta2-adrenoceptor agonism. Br J Clin Pharmacol 2002; 54:231-245.
34. Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 2006; 61:940-944.
35. Wechsler ME, Israel E. beta-adrenergic receptor genotype and response to salmeterol. J Allergy Clin Immunol 2007; 120:218-219.
36. Lee DK, Currie GP, Hall IP, et al. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 2004; 57:68-75.
37. Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370:2118-2125.
38. Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006; 118:809-816.
39. Dudekula N, Arora V, Callaerts-Vegh Z, Bond RA. The temporal hormesis of drug therapies. Dose Response 2005; 3:414-424.
40. Bond RA, Spina D, Parra S, Page CP. Getting to the heart of asthma: can 'beta blockers' be useful to treat asthma? Pharmacol Ther 2007; 115:360-374.
41. Olenchock BA, Fonarow GG, Pan W, et al. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am J Cardiol 2009; 103:295-300.
42. Thottathil P, Acharya J, Moss AJ, et al. Risk of cardiac events in patients with asthma and long-QT syndrome treated with beta(2) agonists. Am J Cardiol 2008; 102:871-874.
43. Ashrafian H, Violaris AG. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. Prim Care Respir J 2005; 14:236-241.
44. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137:715-725.
45. van Gestel YR, Hoeks SE, Sin DD, et al. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med 2008; 178:695-700.
46. Lin R, Peng H, Nguyen LP, et al. Changes in beta 2-adrenoceptor and other signaling proteins produced by chronic administration of 'beta-blockers' in a murine asthma model. Pulm Pharmacol Ther 2008; 21:115-124.
47. Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38:256-262.
48. Nguyen LP, Lin R, Parra S, et al. {beta}2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A 2009; 106:2435-2440.
49. Hanania NA, Singh S, El-Wali R, et al. The safety and effects of the betablocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther 2008; 21:134-141.
50. Lipworth BJ, Williamson PA. Beta blockers for asthma: a double-edged sword. Lancet 2009; 373:104-105.
51. Penn RB. Agonizing over agonism: should asthmatics turn their beta-receptors on or off? Proc Natl Acad Sci U S A 2009; 106:2095-2096.
52. Chupp GL. Say what, beta-blockers for asthma? Am J Respir Cell Mol Biol 2008; 38:249-250.